Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ovarian cancer
Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination treatment of avutometinib and defactinib for a rare form of ovarian cancer. With the commercial name of Avmapki Fakzynja Co-Pack, the combo becomes the first treatment specifically for patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). It affects between 6,000 and 8,000 women in the U.S. and 80,000 globally.
Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination treatment of avutometinib and defactinib for a rare form of ovarian cancer. With the commercial name of Avmapki Fakzynja Co-Pack, the combo becomes the first treatment specifically for patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). It affects between 6,000 and 8,000 women in the U.S. and 80,000 globally.
